• +1-646-491-9876
    • +91-20-67278686

    Search

    Venous Leg Ulcers-Pipeline Review H2 2017

    Venous Leg Ulcers-Pipeline Review H2 2017

    • Report Code ID: RW0001881433
    • Category Life Sciences
    • No. of Pages 75
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Venous Leg Ulcers (Crural ulcer)-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer)-Pipeline Review H2 2017 provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape.

    Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema) discoloration and darkening of skin around the ulcer (known as hemosiderosis) hardened skin around the ulcer which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis) small smooth areas of white skin which may have tiny red spots (known as atrophie blanche) .

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical and Unknown stages are 3 7 1 5 and 2 respectively.

    Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Venous Leg Ulcers (Crural ulcer)-Overview
    Venous Leg Ulcers (Crural ulcer)-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Venous Leg Ulcers (Crural ulcer)-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Venous Leg Ulcers (Crural ulcer)-Companies Involved in Therapeutics Development
    CardioVascular BioTherapeutics Inc
    CytoTools AG
    Daval International Ltd
    Factor Therapeutics Ltd
    FirstString Research Inc
    GangaGen Inc
    Hypo-Stream Ltd
    Leap Therapeutics Inc
    MediWound Ltd
    NovaLead Pharma Pvt Ltd
    Promore Pharma
    RegeneRx Biopharmaceuticals Inc
    RMB-Research GmbH
    Stratatech Corp
    Venous Leg Ulcers (Crural ulcer)-Drug Profiles
    Aimspro-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AUP-16-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CODA-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CureXcell-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CVBT-141B-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    diperoxochloric acid-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EscharEx-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Granexin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LL-37-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NLP-328-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-128-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RGN-137-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-42909-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sodium hypochlorite-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Statmicoll-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VF-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Venous Leg Ulcers (Crural ulcer)-Dormant Projects
    Venous Leg Ulcers (Crural ulcer)-Discontinued Products
    Venous Leg Ulcers (Crural ulcer)-Product Development Milestones
    Featured News & Press Releases
    Apr 07 2017 Factor Therapeutics Phase II Clinical Trial Progress Update
    Dec 20 2016 Factor Therapeutics-First Patient In and Clinical Update
    Nov 07 2016 FDA Clinical Hold Lifted for IND 119526 (VF-001)
    Oct 10 2016 Submission of IND Amendments for Phase II Study of VF-001 in the US
    Aug 03 2016 Factor Therapeutics Announces Formation of Medical Advisory Board
    May 23 2016 CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial
    Dec 17 2015 Tissue Therapies Provides FDA Regulatory Progress Update
    Aug 19 2015 Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers
    Jul 22 2015 RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment
    Jun 29 2015 CytoTools announces positive intermediate results for the European ulcus cruris trial-seamless transition into an approval-relevant phase III trial with less number of patients
    May 13 2015 Successful dialogue with the American Food and Drug Administration (FDA) regarding the expansion of the DermaPro clinical trials programme for the indication ulcus cruris in the USA
    Apr 21 2015 SCRA Technology Ventures Company Shares Phase 2 Results
    Apr 15 2015 CytoTools Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications
    May 05 2014 Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication
    Jan 09 2013 CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Venous Leg Ulcers (Crural ulcer) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by CardioVascular BioTherapeutics Inc H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by CytoTools AG H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by Daval International Ltd H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by Factor Therapeutics Ltd H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by FirstString Research Inc H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by GangaGen Inc H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by Hypo-Stream Ltd H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by Leap Therapeutics Inc H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by MediWound Ltd H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by NovaLead Pharma Pvt Ltd H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by Promore Pharma H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by RegeneRx Biopharmaceuticals Inc H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by RMB-Research GmbH H2 2017
    Venous Leg Ulcers (Crural ulcer)-Pipeline by Stratatech Corp H2 2017
    Venous Leg Ulcers (Crural ulcer)-Dormant Projects H2 2017
    Venous Leg Ulcers (Crural ulcer)-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Venous Leg Ulcers (Crural ulcer) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    CardioVascular BioTherapeutics Inc
    CytoTools AG
    Daval International Ltd
    Factor Therapeutics Ltd
    FirstString Research Inc
    GangaGen Inc
    Hypo-Stream Ltd
    Leap Therapeutics Inc
    MediWound Ltd
    NovaLead Pharma Pvt Ltd
    Promore Pharma
    RegeneRx Biopharmaceuticals Inc
    RMB-Research GmbH
    Stratatech Corp

    Request for Sample

    Report Url https://www.reportsweb.com//venous-leg-ulcers-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//venous-leg-ulcers-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//venous-leg-ulcers-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments